HCP Connect Contributor
Dr. Meera Pillai
Dr. Meera Pillai contributes oncology drug update coverage for HCP Connect, with emphasis on source-verified therapeutic developments and practical clinical context for US-licensed practitioners. This profile links the author's recent clinical coverage, specialty focus, and professional contributor metadata in one place.
Recent Drug Updates
33 total
Oncology
FDA Panel Votes Against Camizestrant for ESR1-Mutated Breast Cancer
Camizestrant: FDA panel votes against approval for ESR1-mutated breast cancer treatment.
Oncology
FDA Approves Imlunestrant for ESR1-Mutated Breast Cancer: 5.5 Months PFS Improvement
Imlunestrant reduces PFS by 5.5 months in ESR1-mutated breast cancer.
Oncology
FDA Advisory Panel Discusses Camizestrant for ESR1-Mutated Breast Cancer
Camizestrant for ESR1-mutated breast cancer: FDA advisory panel evaluates efficacy and safety for HR-positive patients.
Oncology
FDA Approves Relacorilant for Platinum-Resistant Ovarian Cancer: 16 Months OS Improvement
Relacorilant improves overall survival in platinum-resistant ovarian cancer: FDA approval details and trial outcomes.
Oncology
FDA Approves Mirdametinib for Neurofibromatosis Type 1: 41% ORR in ReNeu Trial
Mirdametinib (Gomekli) approved for NF1 plexiform neurofibromas: 41% ORR in adults and 52% in pediatric patients.
Oncology
FDA Approves Telisotuzumab Vedotin for NSCLC: 35% ORR in LUMINOSITY Trial
FDA approves telisotuzumab vedotin for NSCLC: 35% ORR in LUMINOSITY trial.
Oncology
FDA Approves Pembrolizumab for HER2-Positive Gastric Cancer: 10.9 Months PFS in KEYNOTE-811 Trial
FDA approves pembrolizumab for HER2-positive gastric cancer: 10.9 months PFS in KEYNOTE-811 trial.
Oncology
Sonrotoclax Shows 65.5% ORR in BRUIN MCL-321 Trial for MCL
Sonrotoclax achieves 65.5% ORR in BRUIN MCL-321 trial for relapsed refractory mantle cell lymphoma.
Oncology
FDA Approves Datopotamab Deruxtecan for TNBC: 36% ORR in TROPION-Breast02 Trial
Datopotamab deruxtecan achieves 36% ORR in unresectable metastatic TNBC in TROPION-Breast02 trial. FDA approval details.
Oncology
FDA Approves Durvalumab for NMIBC: 32% DFS Improvement in POTOMAC Trial
Durvalumab (Imfinzi) approved for high-risk NMIBC: 32% DFS improvement in POTOMAC trial.
Oncology
FDA Grants Accelerated Approval to Sonrotoclax for Relapsed Refractory Mantle Cell Lymphoma
FDA grants accelerated approval to sonrotoclax (Beqalzi) for relapsed refractory mantle cell lymphoma with 52% overall response rate.
Oncology
FDA Approves Vepdegestrant for ER-Positive Breast Cancer: 5-Month PFS Improvement in VERITAC-2 Trial
FDA approves vepdegestrant (Veppanu) for ESR1-mutated ER-positive breast cancer, showing 5-month PFS improvement in VERITAC-2 trial.
Oncology
FDA Approves Trastuzumab Deruxtecan for Neoadjuvant HER2-Positive Breast Cancer: 67.3% pCR in DESTINY-Breast11 Trial
Trastuzumab deruxtecan (Enhertu) approved for neoadjuvant HER2-positive breast cancer with 67.3% pCR in DESTINY-Breast11 trial.
Oncology
Osimertinib and Pembrolizumab: New First-Line Strategies for NSCLC in 2026
Osimertinib and pembrolizumab are pivotal in NSCLC first-line treatment, improving outcomes based on biomarker selection.
Oncology
NCCN Updates Guidelines: ESR1 Mutation Testing for Breast Cancer Management
NCCN updates guidelines for ESR1 mutation testing in breast cancer: new targeted therapies vepdegestrant and elacestrant.
Oncology
FDA Panel Recommends Capivasertib for PTEN-Deficient mHSPC: New Combination Therapy with Abiraterone
FDA panel recommends capivasertib for PTEN-deficient mHSPC: a new combination therapy with abiraterone.
Oncology
Liquid Biopsy for ESR1 Mutation Testing: Key Insights for Breast Cancer Management
Liquid biopsy for ESR1 mutation testing is crucial for managing ER+ breast cancer, guiding treatment decisions for patients.
Oncology
FDA Approves LYNOZYFIC for Multiple Myeloma: 80% Response Rate in Relapsed Patients
FDA approves LYNOZYFIC for multiple myeloma: 80% response rate in relapsed patients, enhancing treatment options.
Medical Research
Remote Monitoring Cuts Cancer Surgery Recovery Time
Discover how remote perioperative monitoring improves outcomes for cancer surgery patients, reducing recovery time and enhancing care.
Oncology
Targeting TMOD2 to Halt Colorectal Cancer Spread
Discover the crucial role of TMOD2 in colorectal cancer progression and metastasis, and how understanding its mechanisms can inform targeted treatment strategies for improved patie...
Oncology
Lipid Levels Linked to 30% Lower Lymphoma Risk
Discover how abnormal lipid levels impact lymphoid malignancy risk in a study of 403,625 UK Biobank participants with 10.5 years of follow-up.
Oncology
ctDNA Guides Surgery for Recurrence
Learn how circulating tumor DNA can predict metastases and inform surgical decisions for better patient outcomes in oncology.
Oncology
82% Complete Response in BCG-Unresponsive NMIBC
Discover a new treatment option for high-risk BCG-unresponsive NMIBC, offering a complete response in 82% of patients and potentially reducing cystectomy rates.
Oncology
Detect MSI in CRC with 1-Hour Molecular Test
Quickly identify microsatellite instability-high colorectal cancer with a rapid molecular test, guiding targeted therapy decisions for patients.
Oncology
Similar Survival in ES-SCLC with Cis/Carbo Plus Etoposide
Real-world analysis shows comparable efficacy between cisplatin and carboplatin with etoposide in extensive-stage small cell lung cancer treatment.
Oncology
Improve Patient Outcomes with Early Palliative Care
Learn how early palliative care integration can enhance patient quality of life and reduce unnecessary hospitalizations in oncology practices
Medical Research
T Cell Exclusion Mechanisms in B Cell Lymphomas
Discover how ATR-dependent determinants exclude T cells from germinal center dark zones in aggressive B cell lymphomas, shedding light on lymphoma biology and potential therapeutic...
Medical Research
New Therapies May Reactivate Immune System in Resistant Melanoma
Researchers identify potential new strategies to overcome immunotherapy resistance in advanced melanoma, offering hope for improved patient outcomes.
Wellness
Inpatient Treatment Yields Better Outcomes for Dual Diagnosis
Learn how inpatient treatment can improve recovery outcomes for patients with dual diagnosis, prioritizing well-being and reducing recidivism rates effectively.
Healthcare Business
ACA Coverage Cuts Young Adult ED Visits by 30%
Discover how the Affordable Care Act's dependent coverage extension impacts substance-associated ED visits among young adults, reducing healthcare utilization and costs.
Healthcare Business
Cut NSCLC Resistance Rates by 30% with Dual Therapy
Learn how combining two therapies can reduce EGFR and MET resistance in NSCLC, improving treatment strategies and patient outcomes in second-line settings.
Oncology
48% Response Rate in ES-SCLC with Novel Therapy
Ifinatamab deruxtecan yields remarkable efficacy in extensive-stage small cell lung cancer, with a 48.2% overall response rate in previously treated patients.
Digital Health
AI Boosts Cardiac Cath Outcomes by 30%
Discover how AI-powered cardiac catheterization labs improve patient care and outcomes, enhancing interventional cardiology with advanced research and expertise.